Document Classification

Section Type: RESULTS

Text: Over 24 months, in continuous fingolimod groups compared with the group that switched from interferon beta-1a to fingolimod, we recorded lower ARRs (0. 18 [95 % CI 0. 14-0. 22] for 0. 5 mg ; 0. 20 [0. 16-0. 25] for 1. 25 mg ; 0. 33 [0. 27-0. 39] for the switch group ; p < 0. 0001 for both comparisons), fewer new or newly enlarged T2 lesions (p = 0. 035 for 0. 5 mg, p = 0. 068 for 1. 25 mg), and fewer patients with Gd-enhancing T1 lesions (p = 0. 001 for 0. 5 mg fingolimod vs switch group ; p = 0. 002 for 1. 25 mg fingolimod vs switch group).